BRPI0911685A2 - composto, método para o tratamento de uma doença, uso de um composto, composição farmacêutica, e, kit - Google Patents

composto, método para o tratamento de uma doença, uso de um composto, composição farmacêutica, e, kit

Info

Publication number
BRPI0911685A2
BRPI0911685A2 BRPI0911685A BRPI0911685A BRPI0911685A2 BR PI0911685 A2 BRPI0911685 A2 BR PI0911685A2 BR PI0911685 A BRPI0911685 A BR PI0911685A BR PI0911685 A BRPI0911685 A BR PI0911685A BR PI0911685 A2 BRPI0911685 A2 BR PI0911685A2
Authority
BR
Brazil
Prior art keywords
compound
kit
disease
treating
pharmaceutical composition
Prior art date
Application number
BRPI0911685A
Other languages
English (en)
Inventor
Klaus Baek Simonsen
Karsten Juhl
Nikolay Khanzhin
Søren Møller Nielsen
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of BRPI0911685A2 publication Critical patent/BRPI0911685A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
BRPI0911685A 2008-04-24 2009-04-22 composto, método para o tratamento de uma doença, uso de um composto, composição farmacêutica, e, kit BRPI0911685A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/DK2008/050092 WO2008131779A1 (en) 2007-04-26 2008-04-24 Isoquinolinone derivatives as nk3 antagonists
PCT/EP2009/054806 WO2009130240A1 (en) 2008-04-24 2009-04-22 Isoquinolinone derivatives as nk3 antagonists

Publications (1)

Publication Number Publication Date
BRPI0911685A2 true BRPI0911685A2 (pt) 2015-10-13

Family

ID=40848056

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0911685A BRPI0911685A2 (pt) 2008-04-24 2009-04-22 composto, método para o tratamento de uma doença, uso de um composto, composição farmacêutica, e, kit

Country Status (16)

Country Link
US (1) US8420667B2 (pt)
EP (1) EP2276741B1 (pt)
JP (1) JP2011518801A (pt)
KR (1) KR20100134667A (pt)
CN (1) CN102026980A (pt)
AU (1) AU2009239990A1 (pt)
BR (1) BRPI0911685A2 (pt)
CA (1) CA2721260A1 (pt)
CO (1) CO6260134A2 (pt)
EA (1) EA201071234A1 (pt)
ES (1) ES2400501T3 (pt)
IL (1) IL208466A0 (pt)
MX (1) MX2010011266A (pt)
NZ (1) NZ588689A (pt)
WO (2) WO2008131779A1 (pt)
ZA (1) ZA201007126B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008131779A1 (en) * 2007-04-26 2008-11-06 H. Lundbeck A/S Isoquinolinone derivatives as nk3 antagonists
TWI425945B (zh) * 2007-05-28 2014-02-11 Seldar Pharma Inc 四氫異喹啉－１－酮衍生物或其鹽
EA201170074A1 (ru) * 2008-06-23 2011-10-31 Х. Лундбекк А/С Изохинолиноновые производные в качестве антагонистов nk3
WO2010028655A1 (en) * 2008-09-15 2010-03-18 H. Lundbeck A/S Isoquinolinone derivatives as nk3 antagonists
US8242134B2 (en) 2008-09-15 2012-08-14 H. Lundbeck A/S Isoquinolinone derivatives as NK3 antagonists
TW201016688A (en) 2008-10-20 2010-05-01 Lundbeck & Co As H Isoquinolinone derivatives as NK3 antagonists
KR101337163B1 (ko) * 2008-11-14 2013-12-05 에프. 호프만-라 로슈 아게 Ｎｋ3 수용체 길항제로서 퀴나졸린 유도체
TW201143768A (en) 2009-12-15 2011-12-16 Lundbeck & Co As H Pyridone derivatives as NK3 antagonists
US20110224247A1 (en) * 2010-03-12 2011-09-15 H. Lundbeck A/S Azaisoquinolinone derivatives as nk3 antagonists
TW201144311A (en) * 2010-03-12 2011-12-16 Lundbeck & Co As H Azaisoquionolinone derivatives as NK3 antagonists
CA2799579A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
ES2637113T3 (es) * 2011-01-10 2017-10-10 Infinity Pharmaceuticals, Inc. Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas
MX2014002542A (es) 2011-08-29 2014-07-09 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
SG11201402134VA (en) * 2011-11-09 2014-06-27 Abbvie Deutschland Heterocyclic carboxamides useful as inhibitors of phosphodiesterase type 10a
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
ES2670550T3 (es) 2013-10-14 2018-05-30 Eisai R&D Management Co., Ltd. Derivados de quinolina selectivamente sustituidos
SG10202103278TA (en) 2013-10-14 2021-04-29 Eisai R&D Man Co Ltd Selectively substituted quinoline compounds
KR102076820B1 (ko) 2013-10-21 2020-02-13 주식회사 대웅테라퓨틱스 신규한 항진균성 옥소다이하이드로피리딘카보하이드라자이드 유도체
EP3915560A1 (en) 2014-06-25 2021-12-01 Emory University Methods of managing conditioned fear with neurokinin receptor antagonists
ES2965675T3 (es) * 2015-03-16 2024-04-16 Ogeda N V Antagonistas del receptor NK-3 para el tratamiento terapéutico o cosmético del exceso de grasa corporal
KR101613245B1 (ko) 2015-04-27 2016-04-18 주식회사 대웅제약 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
EP3704271B1 (en) 2017-11-02 2026-01-28 California Institute of Technology Neurokinin antagonists and uses thereof
CN113861111B (zh) * 2021-11-23 2023-05-26 浙江工业大学 N-芳基-4-硫(硒)乙基多元环并[c]-1-吡啶酮衍生物及其合成方法和应用
CN116693363B (zh) * 2022-02-24 2025-12-23 帕潘纳(北京)科技有限公司 一种除草剂中间体的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK282721B6 (sk) * 1994-05-27 2002-11-06 Smithkline Beecham S.P.A. Nepeptidové NK3 antagonistické látky, spôsob ich výroby, farmaceutické prostriedky s ich obsahom a ich použitie
GB0318727D0 (en) * 2003-08-08 2003-09-10 Smithkline Beecham Corp Novel compounds
GB0425076D0 (en) 2004-11-12 2004-12-15 Smithkline Beecham Corp Novel compounds
GB0425077D0 (en) 2004-11-12 2004-12-15 Smithkline Beecham Corp Novel compounds
MX2007014831A (es) 2005-06-03 2008-02-15 Astrazeneca Ab Derivados de quinolina como antagonistas de neurocinina-3.
WO2008131779A1 (en) * 2007-04-26 2008-11-06 H. Lundbeck A/S Isoquinolinone derivatives as nk3 antagonists
US8173639B2 (en) 2007-04-26 2012-05-08 H. Lundbeck A/S Isoquinolinone derivatives as NK3 antagonists
EA201170074A1 (ru) 2008-06-23 2011-10-31 Х. Лундбекк А/С Изохинолиноновые производные в качестве антагонистов nk3
US8054446B2 (en) * 2008-08-21 2011-11-08 Carl Zeiss Smt Gmbh EUV lithography apparatus and method for determining the contamination status of an EUV-reflective optical surface
WO2010028655A1 (en) 2008-09-15 2010-03-18 H. Lundbeck A/S Isoquinolinone derivatives as nk3 antagonists
US8242134B2 (en) 2008-09-15 2012-08-14 H. Lundbeck A/S Isoquinolinone derivatives as NK3 antagonists

Also Published As

Publication number Publication date
EA201071234A1 (ru) 2011-04-29
ZA201007126B (en) 2011-12-28
CN102026980A (zh) 2011-04-20
AU2009239990A1 (en) 2009-10-29
CA2721260A1 (en) 2009-10-29
WO2009130240A1 (en) 2009-10-29
US20110130420A1 (en) 2011-06-02
IL208466A0 (en) 2010-12-30
EP2276741A1 (en) 2011-01-26
CO6260134A2 (es) 2011-03-22
EP2276741B1 (en) 2012-12-26
KR20100134667A (ko) 2010-12-23
NZ588689A (en) 2011-09-30
MX2010011266A (es) 2010-11-01
US8420667B2 (en) 2013-04-16
WO2008131779A1 (en) 2008-11-06
ES2400501T3 (es) 2013-04-10
JP2011518801A (ja) 2011-06-30

Similar Documents

Publication Publication Date Title
BRPI0911685A2 (pt) composto, método para o tratamento de uma doença, uso de um composto, composição farmacêutica, e, kit
BR122020011920A2 (pt) composto, composição farmacêutica, método para tratar uma doença, uso de um composto, e processos para a preparação de um composto, e para a fabricação de um composto
BRPI0819799A2 (pt) Composto, intermediário, uso de um composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar uma doença
BRPI0917458A2 (pt) composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto
BRPI0907976A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BR112012016398A2 (pt) Composto imidazopiridinil-aminopiridino substituído, composição farmacêutica que compreende o referido composto e uso do mesmo para o tratamento de uma doença celular proliferativa
BRPI0917705A2 (pt) composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto
BRPI0818244A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença
BRPI0819755A2 (pt) composto, composição farmacêutica, processos para a preparação de um composto e de uma composição farmacêutica, uso de um composto, e, método para tratar ou reduzir o risco de uma doença ou uma condição inflamatória
BRPI0819218A2 (pt) Métodos, estojos e composições para administração de compostos farmacêuticos
BRPI0812851A2 (pt) Composto, composição farmacêutica, métodos para o tratamento de uma doença e de uma condição em um indivíduo, processo para preparar um composto, e, uso de um composto
BRPI0814503A2 (pt) composto, uso de um composto, métodos para produzir um efeito anti-proliferativo em um animal de sangue quente, e para tratar uma doença, e, composição farmacêutica
BRPI0820474A2 (pt) método de tratamento de uma doença, uso de composto, e, composto
BRPI0912539A2 (pt) composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
BRPI1013984A2 (pt) composto , composição farmacêutica, método para tratamento ou profilaxia de uma doença ou condição, e, uso de um composto.
BR112014011671A2 (pt) composto, composição farmacêutica, método para o tratamento de uma doença ou condição, e, uso de um composto
BRPI0922475A2 (pt) composto, composição farmacêutica , método para tratar câncer, e, uso de um composto.
BRPI0907974A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI0913585A2 (pt) composto, método para fabricar um composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de distúrbios
BRPI1009022A2 (pt) "composto, composição farmacêutica, processo para produzir uma composição farmacêutica, uso de um composto, método para tratamento de uma doença ou transtorno e kit"
BRPI0906576A2 (pt) Composição farmacêutica, kit, uso de um composto, e, agente terapêutico para câncer
BRPI0908883A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI0811059A2 (pt) combinação, composição farmacêutica, método para tratar câncer em um animal de sangue quente, e, uso de uma combinação
BRPI0815591A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença, condição ou distúrbio.
BR112012004173A2 (pt) "composto, composição, método para preparar uma composição, e, uso de um composto"

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.